Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A

Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia.

Br J Haematol 91:625-9 (1995)
DOI:10.1111/j.1365-2141.1995.tb05358.x

Sill H, Goldman JM, Cross NC

Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.

Blood 85:2013-6 (1995)

Berggren P, Kumar R, Sakano S, Hemminki L, Wada T, Steineck G, Adolfsson J, Larsson P, Norming U, Wijkstrom H, Hemminki K

Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.

Clin Cancer Res 9:235-42 (2003)

Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C

Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence.

Am J Pathol 155:105-13 (1999)
DOI:10.1016/S0002-9440(10)65105-X

Sibin MK, Bhat DI, Lavanya Ch, Manoj MJ, Aakershita S, Chetan GK

CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.

Tumour Biol 35:1467-72 (2014)
DOI:10.1007/s13277-013-1201-5

Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Nat Genet 47:505-511 (2015)
DOI:10.1038/ng.3252